Chapter 3
WIA-BIO-006 (version 1.0.0, category BIO / Biomedical Engineering) defines one framework for the whole path from a scaffold design to a tissue construct that is cultured, tested, and cleared for regenerative-medicine use. Its stated scope covers natural, synthetic, and hybrid biomaterial scaffolds, 3D bioprinting techniques and protocols, bioreactor design and operation, vascularization and perfusion strategies, and quality control with regulatory compliance. The headline features are scaffold design, bioreactor systems, 3D bioprinting, organ-on-chip microfluidic platforms, vascularization, and quality assurance. The philosophy statement, 弘益人間 (Benefit All Humanity), frames the aim as regenerative medicine that is accessible to all.
The terminology section fixes five terms that the rest of the document relies on:
These definitions matter because the field blurs them in practice. A decellularized organ is an ECM scaffold that was never designed in CAD. A hydrogel bioink is a scaffold that is deposited together with its cells. The standard handles this by treating the scaffold, the bioink, the construct, and the bioreactor run as separate records that point to one another.
An implementation claiming WIA-BIO-006 compliance must provide five components:
| Component | Responsibility named by the standard |
|---|---|
| Scaffold Designer | CAD integration and material selection |
| Bioreactor Controller | Parameter monitoring and control |
| Quality Validator | Automated testing protocols |
| Bioprinting Module | Toolpath generation and cell handling |
| Documentation System | GMP-compliant record keeping |
The standard also lists integration points with sibling WIA specifications: WIA-INTENT for intent-based tissue design requests, WIA-OMNI-API as a biomedical API gateway, WIA-SOCIAL for collaboration on protocols, and WIA-QUANTUM for simulating molecular interactions. They are optional connectors. The tissue-engineering content sits in the five components above, which the remaining sections of this chapter follow.
A scaffold has two jobs that pull in opposite directions. It must be stiff enough to carry load and hold a shape, and it must be porous and degradable enough for cells to migrate in and for new tissue to replace it. The standard organizes the choice into natural, synthetic, and hybrid materials and gives reference constants for each.
| Material | Young's modulus | Porosity range | Degradation time | Biocompatibility |
|---|---|---|---|---|
| Collagen | 1-10 MPa | 70-95% | 2-8 weeks | Excellent |
| Gelatin | 0.1-1 MPa | 80-95% | 1-4 weeks | Excellent |
| Chitosan | 1-2 GPa | 70-90% | 4-12 weeks | Excellent |
| PCL | 200-400 MPa | 60-80% | 6-24 months | Good |
| PLA | 2000-4000 MPa | 50-90% | 6-12 months | Good |
The natural materials carry biological signals. Collagen offers RGD adhesion domains and is prepared by extraction from bovine or porcine sources, salt-precipitation purification, neutralization to pH 7.4, and optional cross-linking with EDC or genipin. Gelatin gels thermally (20-30 °C) and has low immunogenicity. Chitosan is pH-responsive and antimicrobial, and is dissolved at pH 5-6 and freeze-dried into porous structures. Alginate gels instantly with Ca²⁺ or Ba²⁺, but it is soft, at 10-100 kPa. The synthetic polyesters trade that bioactivity for mechanics and predictable degradation. PCL is slow to degrade, which suits bone healing, and is easy to electrospin or 3D print. PLA is stiffer. PGA is very stiff (7 GPa) but degrades in 2-4 weeks and is reserved for fast-resorbing uses such as sutures.
Hybrids resolve the trade-off directly. The reference PCL-collagen composite is 70% PCL and 30% collagen, with a modulus of 50-150 MPa, porosity of 65-80%, and degradation over 3-6 months. It combines PCL's strength with collagen's cell adhesion. The gelatin-alginate blend (ratios from 1:1 to 3:1 gelatin:alginate) gels by both temperature and ionic exchange, reaches 10-50 kPa, and is injectable.
Architecture is specified through porosity and pore size. Porosity is defined in the overview as P = (V_void / V_total) × 100%, with 60-90% as the general optimum. The detailed specification gives a density-based equivalent for measured samples, P = (1 - ρ_apparent / ρ_material) × 100%. The two are the same quantity, computed from geometry in the first case and from weighing in the second. Recommended porosity is tissue-specific:
Pore size is matched to the cell that must enter the scaffold: 100-400 μm for osteoblasts, 50-150 μm for fibroblasts, and 30-100 μm for endothelial cells. Pores that are too small block infiltration and nutrient diffusion. Pores that are too large weaken the scaffold and give cells too little surface to bridge. The same logic explains why the stiffness values spread over orders of magnitude, from kilopascals for alginate to gigapascals for PLA and chitosan. The standard's mechanical quantity is plain stress, σ = F / A, and it says Young's modulus varies by tissue type. Its quality rule is that the engineered construct must match native tissue properties within 20%.
Once a scaffold or bioink is chosen, the construct has to be populated with cells and matured. The standard describes three printing technologies, four seeding methods, and the bioreactors that follow.
| Technology | Principle | Strengths | Limitations |
|---|---|---|---|
| Extrusion | Pneumatic or mechanical extrusion of bioink (10-200 kPa, nozzle 100-1000 μm) | High cell density, multiple materials, low cost | Lower resolution, shear stress on cells |
| Inkjet | Thermal or piezoelectric droplets (1-300 pL, resolution 20-100 μm) | High speed, high resolution, low cost | Restricted to low-viscosity inks (3-12 mPa·s) |
| Laser-assisted (LIFT) | Laser-induced forward transfer (resolution <10 μm) | Highest resolution, viability above 95%, no nozzle clogging | High cost, complex setup, low throughput |
The bioink is where printing and biology meet. A cell-laden hydrogel combines a polymer base (gelatin, alginate, collagen, or hyaluronic acid), a cross-linker (Ca²⁺, 405 nm light, or temperature), cells at 10⁶-10⁸ cells/mL, and optional growth factors such as VEGF, BMP, or FGF. Its rheology must be shear-thinning so that it flows through the nozzle and then holds its shape. The standard requires a storage modulus G' above the loss modulus G" (gel-like behavior), with viscosity of 30-6000 mPa·s. The alternative is a decellularized-ECM bioink: tissue is decellularized with SDS or Triton X-100, solubilized with pepsin at pH 2-3, neutralized to pH 7.4, and then loaded with cells. It keeps tissue-specific biochemical cues that a single-polymer gel cannot reproduce.
The printing protocol runs in three stages. Pre-print preparation covers the CAD model (an STL file), slicing, G-code generation, bioink mixing, printer calibration, and loading sterile cartridges. During printing, the system is initialized with UV sterilization and the nozzle is primed to remove air bubbles. The first layer is treated as critical for adhesion, and the print is watched by camera. Post-print steps are cross-linking (UV for 5-15 minutes, ionic, or thermal), medium addition, incubation at 37 °C and 5% CO₂, and 1-4 weeks of maturation in a bioreactor. Fidelity is measured against the design: F = (1 - |D_actual - D_design| / D_design) × 100%, with a target above 90%. Post-print viability must be at least 80%, with above 90% as the target.
Seeding, for pre-formed scaffolds, is a question of efficiency. The standard lists these methods and efficiencies:
RCF = 1.12 × r × (RPM/1000)². Efficiency is 70-95%.Target density follows D = N_cells / V_scaffold, with a typical range of 10⁶-10⁸ cells/cm³ and tissue-specific guidelines, for example 2 × 10⁷-6 × 10⁷ cells/cm³ for cartilage and 5 × 10⁷-2 × 10⁸ cells/cm³ for liver. Seeding efficiency and density interact. The 10 × 10 × 3 mm scaffold used as the SDK example has a volume of 0.3 cm³, and at the general range it would take between roughly 3 × 10⁵ and 3 × 10⁷ cells. The method has to deliver that number into the pores, not just onto the surface.
Maturation then happens in a bioreactor chosen for the tissue. The spinner flask (40-100 rpm, 50% medium exchange daily) is simple and cheap. The perfusion bioreactor pushes medium through the scaffold with a peristaltic pump, with flow rate Q = v × A, typically 0.1-5 mL/min, shear stress of 0.1-10 dyne/cm², and pressure below 10 kPa. The rotating wall vessel provides a low-shear, simulated-microgravity environment and is listed for cartilage, hepatic tissue, and stem-cell differentiation. Perfusion matters most for thick constructs, where diffusion alone cannot carry oxygen to the core. That is the underlying reason vascularization strategies are a core pillar of the standard.
The standard turns the design steps above into typed requests and a declarative configuration record, so that two systems can exchange the same scaffold without ambiguity. Scaffold design takes a ScaffoldRequest and returns a ScaffoldResponse:
interface ScaffoldRequest {
tissueType: string;
material: BiomaterialType;
porosity: number; // percentage
poreSize: number; // micrometers
dimensions: {
length: number; // mm
width: number; // mm
height: number; // mm
};
}
interface ScaffoldResponse {
id: string;
volume: number; // mm³
surfaceArea: number; // mm²
cellCapacity: number; // cells
mechanicalProperties: MechanicalProperties;
fabricationMethod: string;
}The response carries derived quantities: volume, surface area, and an estimated cell capacity. A designer can therefore check the seeding arithmetic from the previous section before any material is committed. Culture optimization works the same way. A CultureRequest names the tissue construct, the cell type, the duration in days, and the bioreactor type. The CultureResponse returns a flow rate (mL/min), oxygen level (%), temperature (°C), shear stress (dyne/cm²), a predicted maturation time in days, and a quality score between 0 and 1.
The persistent record is the scaffold configuration, which uses snake_case JSON:
{
"scaffold_id": "SCF-2025-001",
"material": {
"type": "pcl-collagen",
"ratio": "70:30",
"crosslinking": "EDC"
},
"architecture": {
"porosity": 75,
"pore_size": 200,
"interconnectivity": 95
},
"dimensions": {
"length": 10,
"width": 10,
"height": 3,
"unit": "mm"
},
"mechanical": {
"youngs_modulus": 50,
"ultimate_strength": 5,
"unit": "MPa"
}
}The record holds the full recipe of a construct: material and ratio, cross-linking chemistry, architecture including interconnectivity, dimensions, and mechanical targets with explicit units. That is what a GMP batch record needs for traceability. The standard also defines an error table. Its documented example is code B001, meaning insufficient porosity, which tells the caller to increase pore size or open up the architecture.
The TypeScript SDK (@wia/bio-006) wraps these calls in functions such as designScaffold, optimizeCulture, assessMechanicalProperties, and validateBiocompatibility. A typical cartilage workflow chains the first two:
const scaffold = designScaffold({
tissueType: 'cartilage',
material: 'pcl-collagen',
porosity: 75,
poreSize: 200, // micrometers
dimensions: { length: 10, width: 10, height: 3 }
});
const culture = optimizeCulture({
tissueConstruct: scaffold,
cellType: 'chondrocytes',
flowRate: 0.5, // mL/min
oxygenLevel: 5, // %
temperature: 37 // °C
});
console.log(culture.predictedMaturation, culture.qualityScore);The command-line tool exposes the same operations to lab scripts:
wia-bio-006 design-scaffold --tissue cartilage --material pcl --porosity 75
wia-bio-006 optimize-culture --cell-type chondrocytes --duration 21
wia-bio-006 assess-mechanics --force 100 --area 0.0001
wia-bio-006 validate-biocompat --material collagen --cell-type fibroblastsThe assess-mechanics example applies σ = F / A directly: 100 N over 0.0001 m² is a stress of 1 MPa, which sits inside the collagen range in the constants table. Provenance and signing mechanisms for published records are handled by the generic WIA release machinery shared across the series. They do not change the biological content of the records above.
Quality in this standard is a set of acceptance criteria attached to each stage of the workflow. Five general rules frame them: sterility must be maintained throughout, post-seeding cell viability must be at least 80%, mechanical integrity must match native tissue within 20%, degradation must be paced to the regeneration timeline, and the immune response to implantation must be minimal.
| Test | Method named in the standard | Acceptance |
|---|---|---|
| Sterility | USP <71> 14-day incubation; LAL endotoxin assay; mycoplasma by PCR or culture | Endotoxin <0.5 EU/mL; tested every batch |
| Cell viability | Calcein AM / ethidium homodimer-1 live/dead staining; MTT/MTS metabolic assay | >80% viability |
| Mechanics | Compression (ASTM D1621); tensile (ASTM D638) | Modulus, ultimate strength, strain at failure reported |
| Cytotoxicity | ISO 10993-5 extract test | >70% viability relative to control |
| Immunogenicity | Cytokines (IL-1β, IL-6, TNF-α), T-cell proliferation, complement (C3a, C5a) | <2-fold increase vs. control |
| In vivo response | Subcutaneous implantation, histology, ISO 10993-6 grading | Score ≤1 |
Functional assays check that the tissue does what it should, beyond simply surviving. Bone constructs are assessed by alkaline phosphatase, osteocalcin, and Alizarin Red calcium staining. Cartilage is assessed by glycosaminoglycans (Alcian Blue), collagen type II immunostaining, and aggrecan. Liver is assessed by albumin secretion, urea synthesis, and CYP450 activity. Gene-expression work uses qRT-PCR, normalized to housekeeping genes such as GAPDH and β-actin, and reports fold change as FC = 2^(-ΔΔCt).
Regulation is described at the level of pathway, not as a legal manual. Most tissue-engineered products are treated as FDA Class II (510(k) notification, GMP, Quality System Regulation), while high-risk products are Class III and need Premarket Approval and clinical trials. GMP calls for validated processes, an ISO 5-7 cleanroom, SOPs, batch-record traceability, and in-process testing. Preclinical work moves from in vitro ISO 10993 biocompatibility to small animals (rat, rabbit) and large animals (pig, sheep), then dose-response and 6-12 month safety studies. Clinical development follows Phase I (safety, 10-30 patients), Phase II (efficacy, 30-100), and Phase III (confirmatory, 100-1000).
The use cases the standard targets show how these pieces combine. They are skin grafts for burns and chronic wounds, cartilage repair, bone regeneration for critical-size defects, cardiac patches after myocardial infarction, engineered replacement organs, tissue models for drug testing, and in vitro disease models.
Summary. WIA-BIO-006 describes a construct as a chain of linked decisions. The material fixes stiffness and degradation. Porosity and pore size are tuned to the cell type. Printing and seeding methods trade resolution against viability. The bioreactor supplies flow and shear during maturation. Every step is recorded in typed requests and a JSON scaffold configuration, and every step is gated by explicit acceptance thresholds. The next chapter moves from this overview to the technical foundation. It looks at the quantities behind the numbers, namely the transport of oxygen and nutrients, the shear forces cells experience, and the vascularization strategies that decide how thick an engineered tissue can usefully be.